Developer docs
API playgroundTry for free, no card

Search company profiles

Quiver Bioscience

Full company profile

uuid0000gqx

Namestring
Quiver Bioscience
Legal namestring
Quiver Bioscience Inc.
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Quiver Bioscience is a Cambridge, MA-based biotechnology company (founded 2014, 101–250 employees) that operates an AI-driven drug discovery platform focused on central nervous system (CNS) diseases. The platform integrates patient-derived induced pluripotent stem cell (iPSC) neuronal models, proprietary all-optical electrophysiology instrumentation (Swarm, Firefly, and Mantis), and AI/ML workflows orchestrated through its QnAi agent. The company's Brain GPS perturbation atlas is built on approximately 18,000 gene perturbations, 3,500 drug fingerprints, and over 1.5 billion action potentials recorded across more than 30 million neurons, enabling target identification, mechanism-of-action profiling, and IND-enabling candidate selection across chronic pain, developmental and epileptic encephalopathies, and neurodevelopmental disorders.

The wholly owned pipeline includes QV-2421 (a Nav1.7 antisense oligonucleotide for chronic pain), a UBE3A ASO for Dup15q syndrome, Nav1.8 ASO, a dual Nav1.7/1.8 ASO, programs in STXBP1, SYNGAP1, FMR1, and SCN8A encephalopathies, and a TSC2 small molecule. Quiver's commercial model is a hybrid of platform-as-a-service and risk-sharing collaborations: it generates revenue from research-funded discovery partnerships (e.g., Angelini Pharma with up to $120M in potential milestones, QurAlis for ALS/FTD, and additional undisclosed pharma partners signed in Q4 2025), supplemented by non-dilutive grant funding (notably a $9.3M NIH HEAL Initiative award in May 2026) and patient-advocacy-backed programs. The 2018 acquisition of Pairnomix brought in epilepsy-focused assets and the STXBP1, SYNGAP1, and SCN8A programs, while the company's recent CEO transition (Graham Dempsey, June 2025) signals a shift from platform development toward clinical-stage execution and broader pharma partnership expansion.

Short descriptiontext

Quiver Bioscience is an AI-native CNS drug discovery company using patient-derived iPSC neurons, all-optical electrophysiology, and proprietary AI/ML to identify and advance antisense oligonucleotide and small-molecule therapeutics for chronic pain, epilepsy, and neurodevelopmental disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS drug discovery, iPSC neuronal models, all-optical electrophysiology, AI-driven therapeutics, antisense oligonucleotide therapeutics
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Analytical Laboratory Instrument Manufacturing334516
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
CNS Drug Discovery & Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Strategic research collaborations and licensing agreements
TypeLicensing Royalties
Description

Multi-year collaboration and licensing deals with pharmaceutical partners. Quiver receives an undisclosed advance payment, support for defined research activities, additional licensing fees, plus milestone payments of up to $120 million and royalties upon partner election of identified drug targets. Example: Angelini Pharma collaboration for DEEs (announced Feb 2026).

quiverbioscience.com
2Research collaboration partnerships
TypeProfessional Services
Description

Targeted research collaborations with biotech/pharma partners covering shared development of platform-derived therapeutic candidates, such as the QurAlis Fragile X Syndrome collaboration (announced May 2025).

quiverbioscience.com
3Non-dilutive grant funding
TypeManaged Services
Description

Government grant funding from NIH and related agencies. Examples include the NIH HEAL Initiative UG3/UH3 cooperative agreement (UG3NS146009) providing up to $9.3 million in direct funding and approximately $20 million in total potential development support for QV-2421. CEO Graham Dempsey has led more than $30M in non-dilutive grant funding from NIH SBIR Programs and CNS Foundations since the company's inception.

quiverbioscience.com
4Strategic mission-driven investments from family offices
TypeOne Time License
Description

Targeted mission-driven strategic investments from family offices (e.g., the Porta family of Argentina) to advance specific wholly-owned programs such as the UBE3A ASO program for Dup15q syndrome.

quiverbioscience.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Quiver Discovery Platform
Description

Proprietary integrated drug discovery platform combining all-optical electrophysiology, patient-derived iPSC neuronal models, single-cell transcriptomics, and AI/ML analytics.

quiverbioscience.com
+2 more records
Core offering1 text field

Quiver Bioscience operates an integrated CNS drug discovery platform that combines patient-derived iPSC neuronal models, proprietary all-optical electrophysiology instruments (Swarm, Firefly, Mantis), and AI/ML analytics (QnAi, Brain GPS perturbation atlas) to identify, validate, and advance therapeutic targets and candidate molecules. On top of the platform, the company runs a wholly-owned therapeutic pipeline of antisense oligonucleotide (ASO) and small molecule drug candidates focused on chronic pain, genetic epilepsies, neurodevelopmental disorders, and rare CNS diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 1.5B+ action potentials and 30M+ individual neurons analyzed across 18,000 gene perturbations and 3,500 drug fingerprints; signals page cites 126,132,905+ neurons and 9.6B+ action potentials to date
+3 more records
Product overview1 text field

Quiver Bioscience offers a single integrated CNS drug discovery and development offering organized as a platform-plus-modules architecture, anchored by the Quiver Discovery Platform with three named modules — Models (patient-derived iPSC neuronal models), Signals (all-optical electrophysiology assays and Swarm/Firefly/Mantis instruments), and Insights (AI models, the perturbation atlas, and the QnAi question-and-answer AI agent) — collectively branded in publications as the Genomic Positioning System (Brain GPS). On top of this platform, Quiver advances a wholly owned therapeutic pipeline of antisense oligonucleotide and small molecule candidates, including lead program QV-2421 (Nav1.7 ASO for chronic neuropathic pain), the UBE3A ASO for Dup15q syndrome, plus wholly owned programs in Nav1.8, STXBP1, SYNGAP1, FMR1, SCN8A, dual Nav1.7/1.8, and TSC2 small molecule, and also runs partnered discovery programs (e.g., with Angelini Pharma, QurAlis, and Vertex/UCB/NIH/Amgen/Takeda/GSK/Merck).

Product and service6 records
1Quiver Discovery Platform
CategoryDrug discovery platform (services)
Description

Integrated three-pillar CNS drug discovery platform combining patient-derived iPSC neuronal models (Models), all-optical electrophysiology measurements (Signals), and AI/ML analytics (Insights) used to identify, validate, and prioritize therapeutic targets and candidate molecules for pharmaceutical and biotechnology partners. Anchored by 1.5B+ action potentials across 30M+ individual neurons, 18,000 gene perturbations, and 3,500 drug fingerprints.

2QV-2421 (Nav1.7 ASO)
CategoryWholly-owned therapeutic candidate (ASO)
Description

Wholly-owned antisense oligonucleotide candidate targeting the Nav1.7 voltage-gated sodium channel for chronic neuropathic pain, advancing through IND-enabling studies and first-in-human clinical trials with support from the NIH HEAL Initiative and Co-PI Dr. Charles Berde at Boston Children's Hospital.

3UBE3A ASO Program (Dup15q syndrome)
CategoryWholly-owned therapeutic candidate (ASO)
Description

Wholly-owned antisense oligonucleotide program for chromosome 15q duplication (Dup15q) syndrome designed to reduce excess UBE3A gene expression, with development candidate selection targeted for 2H 2026. Supported by the Dup15q Alliance collaboration and a strategic investment from the Porta family.

4Wholly-owned CNS ASO and small molecule pipeline (Nav1.8, STXBP1, SYNGAP1, FMR1, SCN8A, dual Nav1.7/1.8, TSC2)
CategoryWholly-owned therapeutic pipeline
Description

Additional wholly-owned therapeutic programs identified by the Quiver platform: Nav1.8 ASO (chronic pain), STXBP1 and SYNGAP1 ASOs (developmental and epileptic encephalopathies), FMR1 (Fragile X Syndrome), SCN8A ASO, dual Nav1.7/1.8 ASO, and TSC2 small molecule (Tuberous Sclerosis).

5Angelini Pharma DEE Collaboration and Licensing Agreement
CategoryPharma collaboration and licensing deal
Description

Multi-year research collaboration and licensing agreement with Angelini Pharma to discover and advance novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs); Quiver is eligible for up to $120 million in milestone payments plus royalties and Angelini secures exclusive global license rights to collaboration-generated drug targets.

6QurAlis Fragile X Syndrome Research Collaboration
CategoryBiotech research collaboration
Description

Research collaboration with QurAlis to advance a novel therapeutic approach for Fragile X Syndrome using Quiver's discovery platform; QurAlis logo also appears on Quiver's pipeline page for the FMR1 program.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeOthersAnnounced on2026-05-04
Description

Phased UG3/UH3 cooperative agreement (award number UG3NS146009) under NIH's Helping to End Addiction Long-term (HEAL) Initiative, providing up to $9.3 million in direct funding and access to NIH-supported CMC and IND-enabling development resources representing total potential development support of approximately $20 million. Funds advancement of QV-2421 (Nav1.7 ASO) for chronic neuropathic pain through preclinical studies and a first-in-human Phase Ib trial in erythromelalgia patients.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-04
Description

Established collaboration with Dr. Charles Berde (Sara Page Mayo Chair in Pediatric Pain Medicine; Professor of Anesthesia at Harvard Medical School) as Co-Principal Investigator of the NIH HEAL Initiative award. Dr. Berde will conduct the Phase Ib trial of QV-2421 in patients affected by erythromelalgia. He also serves as a Senior Associate on Quiver's Scientific Advisory Board.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Multi-year collaboration and licensing agreement to discover and advance novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs), a group of rare genetic diseases causing severe treatment-resistant seizures in children. Quiver will leverage its AI-powered drug discovery platform combining human neuronal models, single-cell transcriptomics, and optical electrophysiology; Angelini Pharma will provide its brain health and epilepsy drug development expertise. Quiver receives an undisclosed advance payment plus support for defined research activities and additional licensing fees; Quiver is also eligible to receive additional milestone payments of up to $120 million and royalties upon Angelini's election of identified drug targets. Angelini secures exclusive global license rights to collaboration-generated drug targets.

Strategic tierMinorTypeOthersAnnounced on2026-02-23
Description

Acted as transaction advisor to Quiver Bioscience on the Angelini Pharma collaboration and licensing agreement.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-15
Description

Research collaboration to advance a novel therapeutic approach for Fragile X Syndrome using Quiver's discovery platform. QurAlis is also referenced on Quiver's pipeline table for the FMR1 (Fragile X Syndrome) program and is shown as a pipeline partner logo on the website, indicating an integrated co-development relationship combining QurAlis' therapeutic expertise with Quiver's platform capabilities.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-03-19
Description

Collaboration to advance Quiver's antisense oligonucleotide therapeutic program for Dup15q syndrome (UBE3A ASO). The Dup15q Alliance is a nonprofit that supports scientific and clinical research toward effective therapeutics and connects Quiver to affected families and clinical sites. The Alliance welcomed the April 2026 strategic investment from the Porta family as 'powerful signal of what's possible when families, science, and community come together around a shared goal.'

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company focused on neurodegenerative and CNS diseases, using human tissue-based disease models and machine learning to identify therapeutic targets. Directly comparable to Quiver in its application of AI/ML on human CNS biology for target identification and partner-led drug development.

TypeBroad incumbent
Description

Publicly traded AI drug discovery company combining high-throughput biology, chemistry, and machine learning across multiple therapeutic areas. While broader in scope than Quiver, Recursion's platform approach of integrating proprietary wetware, automated experimentation, and AI maps directly to Quiver's lab-in-the-loop architecture and is a clear scale competitor in the AI-discovery space.

TypeBroad incumbent
Description

Machine-learning-driven drug discovery company combining induced pluripotent stem cell (iPSC) biology, CRISPR genomics, and AI/ML to predict drug behavior. Closely comparable to Quiver in its reliance on iPSC-derived human cell models and AI/ML for CNS and metabolic disease target identification.

TypeBroad incumbent
Description

Publicly traded computational chemistry and molecular simulation company partnering with pharma on AI-enabled drug design. Comparable to Quiver as a software- and physics-driven platform that licenses tools and co-discovers candidates, though focused on small-molecule design rather than functional CNS biology.

TypeEmerging player
Description

Clinical-stage CNS-focused biotech developing precision medicines for neuroscience indications including depression, Alzheimer's agitation, and Parkinson's. Comparable to Quiver in CNS focus and B2B/partnership-oriented business model, though at a more advanced clinical stage.

TypeEmerging player
Description

CNS-focused clinical-stage biotech developing precision medicines for ALS and Fragile X Syndrome. Directly comparable as an active collaboration partner of Quiver on the Fragile X Syndrome program, operating in the same CNS precision-medicine space with overlapping scientific leadership (Jonathan Fleming, former Q-State CEO, serves on both boards).

TypeBroad incumbent
Description

CNS-focused biotech developing therapies for schizophrenia and other neuropsychiatric conditions; acquired by Bristol Myers Squibb in 2024. Comparable as a CNS-focused partnership/acquisition target and indicator of pharma demand for CNS pipeline assets in the same therapeutic space Quiver is pursuing.

8Cognito Therapeutics
TypeEmerging player
Description

Clinical-stage neuroscience company developing disease-modifying therapeutics for Alzheimer's disease using gamma-frequency neuromodulation. Comparable as a platform-driven CNS therapeutics company with multiple pharma partnerships and academic medical center collaborations in neurological indications.

TypeEmerging player
Description

AI/ML analytics company that applies machine learning to EEG and other electrophysiology datasets to characterize CNS drug activity. Comparable to Quiver in applying computational analysis to large-scale neuronal electrophysiology data for CNS drug development, though focused on EEG rather than optical electrophysiology.

TypeBroad incumbent
Description

Commercial-stage leader in RNA interference (RNAi) therapeutics with CNS pipeline expansion. Comparable as an oligonucleotide modality leader whose CNS pipeline validates the broader ASO/siRNA approach that Quiver's wholly-owned ASO programs (Nav1.7, Nav1.8, STXBP1, SYNGAP1, UBE3A) are pursuing.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability14 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quiver Bioscience

CNS Drug Discovery & Therapeuticsquiverbioscience.com

Quiver Bioscience is an AI-native CNS drug discovery company using patient-derived iPSC neurons, all-optical electrophysiology, and proprietary AI/ML to identify and advance antisense oligonucleotide and small-molecule therapeutics for chronic pain, epilepsy, and neurodevelopmental disorders.

What Quiver Bioscience does

Quiver Bioscience is a Cambridge, MA-based biotechnology company (founded 2014, 101–250 employees) that operates an AI-driven drug discovery platform focused on central nervous system (CNS) diseases. The platform integrates patient-derived induced pluripotent stem cell (iPSC) neuronal models, proprietary all-optical electrophysiology instrumentation (Swarm, Firefly, and Mantis), and AI/ML workflows orchestrated through its QnAi agent. The company's Brain GPS perturbation atlas is built on approximately 18,000 gene perturbations, 3,500 drug fingerprints, and over 1.5 billion action potentials recorded across more than 30 million neurons, enabling target identification, mechanism-of-action profiling, and IND-enabling candidate selection across chronic pain, developmental and epileptic encephalopathies, and neurodevelopmental disorders.

The wholly owned pipeline includes QV-2421 (a Nav1.7 antisense oligonucleotide for chronic pain), a UBE3A ASO for Dup15q syndrome, Nav1.8 ASO, a dual Nav1.7/1.8 ASO, programs in STXBP1, SYNGAP1, FMR1, and SCN8A encephalopathies, and a TSC2 small molecule. Quiver's commercial model is a hybrid of platform-as-a-service and risk-sharing collaborations: it generates revenue from research-funded discovery partnerships (e.g., Angelini Pharma with up to $120M in potential milestones, QurAlis for ALS/FTD, and additional undisclosed pharma partners signed in Q4 2025), supplemented by non-dilutive grant funding (notably a $9.3M NIH HEAL Initiative award in May 2026) and patient-advocacy-backed programs. The 2018 acquisition of Pairnomix brought in epilepsy-focused assets and the STXBP1, SYNGAP1, and SCN8A programs, while the company's recent CEO transition (Graham Dempsey, June 2025) signals a shift from platform development toward clinical-stage execution and broader pharma partnership expansion.

Quiver Bioscience firmographics

Firmographics
Name
Quiver Bioscience
Legal name
Quiver Bioscience Inc.
Website
https://quiverbioscience.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Quiver Bioscience is an AI-native CNS drug discovery company using patient-derived iPSC neurons, all-optical electrophysiology, and proprietary AI/ML to identify and advance antisense oligonucleotide and small-molecule therapeutics for chronic pain, epilepsy, and neurodevelopmental disorders.
Ownership category
akta.pro rank

Quiver Bioscience industry classification

Industry
Product category
CNS Drug Discovery & Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • CNS drug discovery
  • IPSC neuronal models
  • All-optical electrophysiology
  • AI-driven therapeutics
  • Antisense oligonucleotide therapeutics

Where Quiver Bioscience is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Quiver Bioscience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Strategic research collaborations and licensing agreements: Multi-year collaboration and licensing deals with pharmaceutical partners. Quiver receives an undisclosed advance payment, support for defined research activities, additional licensing fees, plus milestone payments of up to $120 million and royalties upon partner election of identified drug targets. Example: Angelini Pharma collaboration for DEEs (announced Feb 2026).
  2. Research collaboration partnerships: Targeted research collaborations with biotech/pharma partners covering shared development of platform-derived therapeutic candidates, such as the QurAlis Fragile X Syndrome collaboration (announced May 2025).
  3. Non-dilutive grant funding: Government grant funding from NIH and related agencies. Examples include the NIH HEAL Initiative UG3/UH3 cooperative agreement (UG3NS146009) providing up to $9.3 million in direct funding and approximately $20 million in total potential development support for QV-2421. CEO Graham Dempsey has led more than $30M in non-dilutive grant funding from NIH SBIR Programs and CNS Foundations since the company's inception.
  4. Strategic mission-driven investments from family offices: Targeted mission-driven strategic investments from family offices (e.g., the Porta family of Argentina) to advance specific wholly-owned programs such as the UBE3A ASO program for Dup15q syndrome.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Quiver Bioscience product offering

Product offering

Core offering

Quiver Bioscience operates an integrated CNS drug discovery platform that combines patient-derived iPSC neuronal models, proprietary all-optical electrophysiology instruments (Swarm, Firefly, Mantis), and AI/ML analytics (QnAi, Brain GPS perturbation atlas) to identify, validate, and advance therapeutic targets and candidate molecules. On top of the platform, the company runs a wholly-owned therapeutic pipeline of antisense oligonucleotide (ASO) and small molecule drug candidates focused on chronic pain, genetic epilepsies, neurodevelopmental disorders, and rare CNS diseases.

Product overview

Quiver Bioscience offers a single integrated CNS drug discovery and development offering organized as a platform-plus-modules architecture, anchored by the Quiver Discovery Platform with three named modules — Models (patient-derived iPSC neuronal models), Signals (all-optical electrophysiology assays and Swarm/Firefly/Mantis instruments), and Insights (AI models, the perturbation atlas, and the QnAi question-and-answer AI agent) — collectively branded in publications as the Genomic Positioning System (Brain GPS). On top of this platform, Quiver advances a wholly owned therapeutic pipeline of antisense oligonucleotide and small molecule candidates, including lead program QV-2421 (Nav1.7 ASO for chronic neuropathic pain), the UBE3A ASO for Dup15q syndrome, plus wholly owned programs in Nav1.8, STXBP1, SYNGAP1, FMR1, SCN8A, dual Nav1.7/1.8, and TSC2 small molecule, and also runs partnered discovery programs (e.g., with Angelini Pharma, QurAlis, and Vertex/UCB/NIH/Amgen/Takeda/GSK/Merck).

Differentiator

Problem solved

Functional benefit

Brands

  • Quiver Discovery Platform: Proprietary integrated drug discovery platform combining all-optical electrophysiology, patient-derived iPSC neuronal models, single-cell transcriptomics, and AI/ML analytics.
  • QnAi (Quiver's Question and Answer AI)
  • Brain GPS (Genomic Positioning System)

Products and services

  • Quiver Discovery Platform Integrated three-pillar CNS drug discovery platform combining patient-derived iPSC neuronal models (Models), all-optical electrophysiology measurements (Signals), and AI/ML analytics (Insights) used to identify, validate, and prioritize therapeutic targets and candidate molecules for pharmaceutical and biotechnology partners. Anchored by 1.5B+ action potentials across 30M+ individual neurons, 18,000 gene perturbations, and 3,500 drug fingerprints.
  • QV-2421 (Nav1.7 ASO) Wholly-owned antisense oligonucleotide candidate targeting the Nav1.7 voltage-gated sodium channel for chronic neuropathic pain, advancing through IND-enabling studies and first-in-human clinical trials with support from the NIH HEAL Initiative and Co-PI Dr. Charles Berde at Boston Children's Hospital.
  • UBE3A ASO Program (Dup15q syndrome) Wholly-owned antisense oligonucleotide program for chromosome 15q duplication (Dup15q) syndrome designed to reduce excess UBE3A gene expression, with development candidate selection targeted for 2H 2026. Supported by the Dup15q Alliance collaboration and a strategic investment from the Porta family.
  • Wholly-owned CNS ASO and small molecule pipeline (Nav1.8, STXBP1, SYNGAP1, FMR1, SCN8A, dual Nav1.7/1.8, TSC2) Additional wholly-owned therapeutic programs identified by the Quiver platform: Nav1.8 ASO (chronic pain), STXBP1 and SYNGAP1 ASOs (developmental and epileptic encephalopathies), FMR1 (Fragile X Syndrome), SCN8A ASO, dual Nav1.7/1.8 ASO, and TSC2 small molecule (Tuberous Sclerosis).
  • Angelini Pharma DEE Collaboration and Licensing Agreement Multi-year research collaboration and licensing agreement with Angelini Pharma to discover and advance novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs); Quiver is eligible for up to $120 million in milestone payments plus royalties and Angelini secures exclusive global license rights to collaboration-generated drug targets.
  • QurAlis Fragile X Syndrome Research Collaboration Research collaboration with QurAlis to advance a novel therapeutic approach for Fragile X Syndrome using Quiver's discovery platform; QurAlis logo also appears on Quiver's pipeline page for the FMR1 program.

Quantifiable outcome

  • 1.5B+ action potentials and 30M+ individual neurons analyzed across 18,000 gene perturbations and 3,500 drug fingerprints; signals page cites 126,132,905+ neurons and 9.6B+ action potentials to date
  • +3 more outcomes

Companies that use Quiver Bioscience

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Quiver Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability14 records

Feature6 records

Quiver Bioscience partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, flagship and minor.

  • National Institutes of Health (NIH) — National Institute of Neurological Disorders and Stroke (NINDS), HEAL InitiativecoreOthers · 4 May 2026Phased UG3/UH3 cooperative agreement (award number UG3NS146009) under NIH's Helping to End Addiction Long-term (HEAL) Initiative, providing up to $9.3 million in direct funding and access to NIH-supported CMC and IND-enabling development resources representing total potential development support of approximately $20 million. Funds advancement of QV-2421 (Nav1.7 ASO) for chronic neuropathic pain through preclinical studies and a first-in-human Phase Ib trial in erythromelalgia patients.
  • Boston Children's Hospital (Dr. Charles Berde, MD, PhD)coreStrategic or Co-development Partner · 4 May 2026Established collaboration with Dr. Charles Berde (Sara Page Mayo Chair in Pediatric Pain Medicine; Professor of Anesthesia at Harvard Medical School) as Co-Principal Investigator of the NIH HEAL Initiative award. Dr. Berde will conduct the Phase Ib trial of QV-2421 in patients affected by erythromelalgia. He also serves as a Senior Associate on Quiver's Scientific Advisory Board.
  • Angelini PharmaflagshipStrategic or Co-development Partner · 23 February 2026Multi-year collaboration and licensing agreement to discover and advance novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs), a group of rare genetic diseases causing severe treatment-resistant seizures in children. Quiver will leverage its AI-powered drug discovery platform combining human neuronal models, single-cell transcriptomics, and optical electrophysiology; Angelini Pharma will provide its brain health and epilepsy drug development expertise. Quiver receives an undisclosed advance payment plus support for defined research activities and additional licensing fees; Quiver is also eligible to receive additional milestone payments of up to $120 million and royalties upon Angelini's election of identified drug targets. Angelini secures exclusive global license rights to collaboration-generated drug targets.
  • Destum PartnersminorOthers · 23 February 2026Acted as transaction advisor to Quiver Bioscience on the Angelini Pharma collaboration and licensing agreement.
  • QurAliscoreStrategic or Co-development Partner · 15 May 2025Research collaboration to advance a novel therapeutic approach for Fragile X Syndrome using Quiver's discovery platform. QurAlis is also referenced on Quiver's pipeline table for the FMR1 (Fragile X Syndrome) program and is shown as a pipeline partner logo on the website, indicating an integrated co-development relationship combining QurAlis' therapeutic expertise with Quiver's platform capabilities.
  • Dup15q AlliancecoreGTM or Marketing Partner · 19 March 2025Collaboration to advance Quiver's antisense oligonucleotide therapeutic program for Dup15q syndrome (UBE3A ASO). The Dup15q Alliance is a nonprofit that supports scientific and clinical research toward effective therapeutics and connects Quiver to affected families and clinical sites. The Alliance welcomed the April 2026 strategic investment from the Porta family as 'powerful signal of what's possible when families, science, and community come together around a shared goal.'

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Quiver Bioscience competitors and assessment

Company assessment

Direct peers

  • Verge Genomics: AI-driven drug discovery company focused on neurodegenerative and CNS diseases, using human tissue-based disease models and machine learning to identify therapeutic targets. Directly comparable to Quiver in its application of AI/ML on human CNS biology for target identification and partner-led drug development.

Broad incumbents

  • Recursion Pharmaceuticals: Publicly traded AI drug discovery company combining high-throughput biology, chemistry, and machine learning across multiple therapeutic areas. While broader in scope than Quiver, Recursion's platform approach of integrating proprietary wetware, automated experimentation, and AI maps directly to Quiver's lab-in-the-loop architecture and is a clear scale competitor in the AI-discovery space.
  • Insitro: Machine-learning-driven drug discovery company combining induced pluripotent stem cell (iPSC) biology, CRISPR genomics, and AI/ML to predict drug behavior. Closely comparable to Quiver in its reliance on iPSC-derived human cell models and AI/ML for CNS and metabolic disease target identification.
  • Schrödinger: Publicly traded computational chemistry and molecular simulation company partnering with pharma on AI-enabled drug design. Comparable to Quiver as a software- and physics-driven platform that licenses tools and co-discovers candidates, though focused on small-molecule design rather than functional CNS biology.
  • Karuna Therapeutics: CNS-focused biotech developing therapies for schizophrenia and other neuropsychiatric conditions; acquired by Bristol Myers Squibb in 2024. Comparable as a CNS-focused partnership/acquisition target and indicator of pharma demand for CNS pipeline assets in the same therapeutic space Quiver is pursuing.
  • Alnylam Pharmaceuticals: Commercial-stage leader in RNA interference (RNAi) therapeutics with CNS pipeline expansion. Comparable as an oligonucleotide modality leader whose CNS pipeline validates the broader ASO/siRNA approach that Quiver's wholly-owned ASO programs (Nav1.7, Nav1.8, STXBP1, SYNGAP1, UBE3A) are pursuing.

Emerging players

  • Neumora Therapeutics: Clinical-stage CNS-focused biotech developing precision medicines for neuroscience indications including depression, Alzheimer's agitation, and Parkinson's. Comparable to Quiver in CNS focus and B2B/partnership-oriented business model, though at a more advanced clinical stage.
  • QurAlis: CNS-focused clinical-stage biotech developing precision medicines for ALS and Fragile X Syndrome. Directly comparable as an active collaboration partner of Quiver on the Fragile X Syndrome program, operating in the same CNS precision-medicine space with overlapping scientific leadership (Jonathan Fleming, former Q-State CEO, serves on both boards).
  • Cognito Therapeutics: Clinical-stage neuroscience company developing disease-modifying therapeutics for Alzheimer's disease using gamma-frequency neuromodulation. Comparable as a platform-driven CNS therapeutics company with multiple pharma partnerships and academic medical center collaborations in neurological indications.
  • Beacon Biosignals: AI/ML analytics company that applies machine learning to EEG and other electrophysiology datasets to characterize CNS drug activity. Comparable to Quiver in applying computational analysis to large-scale neuronal electrophysiology data for CNS drug development, though focused on EEG rather than optical electrophysiology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Quiver Bioscience social profiles

Digital presence

Quiver Bioscience compliance and trust

Trust signal

Compliance1 record

Quiver Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quiver Bioscience leadership team

Management profile

Number of profiles

Profiles19 records

Quiver Bioscience funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quiver Bioscience M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quiver Bioscience

What does Quiver Bioscience do?

Quiver Bioscience operates an integrated CNS drug discovery platform that combines patient-derived iPSC neuronal models, proprietary all-optical electrophysiology instruments (Swarm, Firefly, Mantis), and AI/ML analytics (QnAi, Brain GPS perturbation atlas) to identify, validate, and advance therapeutic targets and candidate molecules. On top of the platform, the company runs a wholly-owned therapeutic pipeline of antisense oligonucleotide (ASO) and small molecule drug candidates focused on chronic pain, genetic epilepsies, neurodevelopmental disorders, and rare CNS diseases.

Is Quiver Bioscience a public or private company?

Quiver Bioscience is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Quiver Bioscience founded?

Quiver Bioscience was founded in 2014. It employs 11 to 50 people.

Where is Quiver Bioscience based?

Quiver Bioscience is headquartered in Cambridge, United States, in the North America region.

How does Quiver Bioscience make money?

Four revenue lines are on record. Strategic research collaborations and licensing agreements are the primary driver. The others are research collaboration partnerships, non-dilutive grant funding and strategic mission-driven investments from family offices.

Who are Quiver Bioscience's main competitors?

Verge Genomics is listed as a direct peer. Broad incumbents are Recursion Pharmaceuticals, Insitro, Schrödinger, Karuna Therapeutics and Alnylam Pharmaceuticals. Emerging players are Neumora Therapeutics, QurAlis, Cognito Therapeutics and Beacon Biosignals.

Does Quiver Bioscience have an API?

No public API is recorded for Quiver Bioscience.

What industry is Quiver Bioscience in?

Quiver Bioscience's product category is CNS Drug Discovery & Therapeutics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceQuiver Bioscience Receives NIH HEAL Initiative Award to Advance Nav1.7 Antisense Therapy for Chronic Pain Through Early Clinical TrialsQuiver Bioscience has received a multi-year grant from the National Institutes of Health (NIH) to advance its Nav1.7-targeted antisense oligonucleotide therapy, QV-2421, through clinical trials for chronic neuropathic pain. The grant provides up to $9.3 million in funding along with access to NIH resources, potentially totaling $20 million in development support. This initiative is part of the NIH's HEAL Initiative aimed at combating the opioid crisis and improving chronic pain management.YahooQuiver Bioscience Receives NIH HEAL Initiative Award to Advance Nav1.7 Antisense Therapy for Chronic Pain Through Early Clinical TrialsQuiver Bioscience received a multi-year NIH HEAL Initiative grant to advance its Nav1.7-targeted antisense oligonucleotide QV-2421 for chronic neuropathic pain. The award provides up to $9.3 million in direct funding and access to development resources, supporting preclinical and first-in-human trials. The company plans a Phase Ib trial in erythromelalgia patients.BioWorldInvestment to advance Quiver’s ASO for Dup15q syndromeQuiver Bioscience received a strategic investment from the Porta family office (Argentina) to advance its antisense oligonucleotide program for Dup15q syndrome. The funding will support preclinical activities, including safety studies for candidate selection as the program moves toward clinical development.BioSpaceQuiver Bioscience Receives Strategic Investment From the Porta Family to Advance UBE3A ASO Therapeutic Program for Dup15q SyndromeQuiver Bioscience received a strategic investment from the Porta family to advance its antisense oligonucleotide program for Dup15q syndrome. The funding will support preclinical safety studies, with a development candidate expected in 2H 2026. Dup15q has no disease-modifying treatments, and the investment aims to accelerate a potential therapy.Business Wire BlogQuiver Bioscience Receives Strategic Investment From the Porta Family to Advance UBE3A ASO Therapeutic Program for Dup15q SyndromeQuiver Bioscience has secured a strategic investment from the Porta family office to fund preclinical activities for its antisense oligonucleotide therapeutic program targeting Dup15q syndrome. The funding will support safety studies and toxicology assessments aimed at selecting a final development candidate by the second half of 2026. This investment addresses a significant unmet medical need, as there are currently no disease-modifying treatments available for this neurodevelopmental disorder.VC News DailyQuiver Bioscience Receives Strategic InvestmentQuiver Bioscience announced a targeted investment from the Porta family to fund preclinical activities for its CNS disorder therapeutic program. The investment aims to support safety studies and development of its antisense oligonucleotide (ASO) for Dup15q syndrome.BioWorldAngelini and Quiver Bioscience partner in genetic epilepsiesAngelini Pharma SpA and Quiver Bioscience Inc. have entered into a multiyear collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. Under the agreement, Angelini Pharma will leverage Quiver Bioscience's technology platform to study developmental and epileptic encephalopathies. The partnership represents a strategic expansion of Angelini's neurology and psychiatric pipeline through external innovation.PharmiWeb.comAngelini Pharma and Quiver Bioscience announce strategic research collaboration and licensing agreement to discover and advance Novel Therapeutics for Genetic EpilepsiesAngelini Pharma and Quiver Bioscience have entered into a multi-year collaboration and licensing agreement to discover and advance novel therapeutics for Developmental and Epileptic Encephalopathies (DEEs), a group of rare genetic epilepsies affecting children worldwide. Under the terms, Quiver receives an undisclosed upfront payment and is eligible for milestone payments of up to $120 million plus royalties upon Angelini's election of identified drug targets. The partnership combines Quiver's AI-driven drug discovery platform and human neuronal models with Angelini Pharma's brain health and epilepsy drug development expertise.FierceBiotechAngelini nocks an AI arrow with $120M Quiver Bioscience dealRome-based Angelini Pharma has signed a multi-year collaboration with Massachusetts biotech Quiver Bioscience to advance novel therapies for genetic epilepsies and developmental epileptic encephalopathies, with Quiver eligible to receive up to $120 million in milestone payments plus potential royalties. The deal gives Angelini exclusive access to Quiver's AI-powered genomic positioning system technology for drug discovery and safety assessment targeting treatment-resistant seizures in rare pediatric diseases. The partnership reflects a growing trend of AI-driven drug development deals in biopharma, following similar agreements such as Eli Lilly's $1 billion AI lab with Nvidia and Takeda's $1.7 billion deal with Iambic Therapeutics.AETOSWireAngelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic EpilepsiesAngelini Pharma and Quiver Bioscience announced a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. Quiver will receive an undisclosed advance payment and up to $120 million in milestone payments, with exclusive data access for Angelini. The partnership aims to develop differentiated therapies for Developmental and Epileptic Encephalopathies.